KRAS and colorectal carcinoma: In models of mutant KRAS CRC, ASNS expression is upregulated by the KRAS-activated signaling pathway, which increases levels of Asn and decreases levels of aspartate (Asp, the metabolic substrate for ASNs) (Toda et al., 2016).